At a glance
- Originator Bayer
- Class Antiallergics; Antiasthmatics; Quinolines; Small molecules
- Mechanism of Action 5-lipoxygenase activating protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma; Bronchitis; Chronic obstructive pulmonary disease; Ischaemic heart disorders; Rheumatoid arthritis